(Q45841458)

English

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease (English)

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

0 references

1 reference

based on heuristic

inferred from title

Crohn's disease

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

Richard N. Fedorak

6

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

Gerald W Dryden

0 references

1

object named as

Bruce E Sands

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

author name string

Eric W Jacobson

2

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

Thomas Sylwestrowicz

3

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

Ziad Younes

4

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

Gerald Dryden

5

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

Susan Greenbloom

7

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

publication date

1 July 2010

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

Inflammatory Bowel Diseases

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

16

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

7

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

1209-1218

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

Unravelling the pathogenesis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

Interleukin-12 and the regulation of innate resistance and adaptive immunity

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

The IL-23/IL-17 axis in inflammation

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

Anti-interleukin-12 antibody for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21159

21 January 2018

Identifiers

10.1002/IBD.21159

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

release_vmhhwznukjawhcvlnjrbpzhxyi

1 reference

https://api.fatcat.wiki/v0/release/vmhhwznukjawhcvlnjrbpzhxyi

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

16 December 2017

http://europepmc.org/abstract/MED/19918967

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45841458&oldid=2085307407"